Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Li, 2020, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, 382, 1199, 10.1056/NEJMoa2001316
Liu, 2020, Detection of Covid-19 in children in early January 2020 in Wuhan, China, N Engl J Med, 382, 1370, 10.1056/NEJMc2003717
CDC COVID-19 Response Team, 2020, Coronavirus disease 2019 in children—United States, February 12–April 2, 2020, MMWR Morb Mortal Wkly Rep, 69, 422, 10.15585/mmwr.mm6914e4
Wu, 2020;, Co-infection and other clinical characteristics of COVID-19 in children, Pediatrics, 146, e20200961, 10.1542/peds.2020-0961
Shekerdemian, 2020, Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units [manuscript published online ahead of print May 11, 2020], JAMA Pediatr, 10.1001/jamapediatrics.2020.1948
CDC COVID-19 Response Team, 2020, Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020, MMWR Morb Mortal Wkly Rep, 69, 343, 10.15585/mmwr.mm6912e2
Guan, 2020;, Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis, Eur Respir J, 55, 2000547, 10.1183/13993003.00547-2020
Castagnoli, 2020, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review [manuscript published online ahead of print April 22, 2020], JAMA Pediatr, 10.1001/jamapediatrics.2020.1467
Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, 382, 727, 10.1056/NEJMoa2001017
Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5
Chen, 2020, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest, 130, 2620, 10.1172/JCI137244
Mo, 2020, Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China [manuscript published online ahead of print March 16, 2020], Clin Infect Dis, 10.1093/cid/ciaa270
Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 323, 1061, 10.1001/jama.2020.1585
Shi, 2020, Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China, JAMA Cardiol, 5, 802, 10.1001/jamacardio.2020.0950
Inciardi, 2020, Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 1, 10.1001/jamacardio.2020.1096
Tisoncik, 2012, Into the eye of the cytokine storm, Microbiol Mol Biol Rev, 76, 16, 10.1128/MMBR.05015-11
Channappanavar, 2017, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin Immunopathol, 39, 529, 10.1007/s00281-017-0629-x
Huang, 2005, An interferon-gamma-related cytokine storm in SARS patients, J Med Virol, 75, 185, 10.1002/jmv.20255
Zhang, 2004, Analysis of serum cytokines in patients with severe acute respiratory syndrome, Infect Immun, 72, 4410, 10.1128/IAI.72.8.4410-4415.2004
Nicholls, 2003, Lung pathology of fatal severe acute respiratory syndrome, Lancet, 361, 1773, 10.1016/S0140-6736(03)13413-7
Gu, 2005, Multiple organ infection and the pathogenesis of SARS, J Exp Med, 202, 415, 10.1084/jem.20050828
de Jong, 2006, Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia, Nat Med, 12, 1203, 10.1038/nm1477
Huang, 2014, Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9, PLoS One, 9, e101788, 10.1371/journal.pone.0101788
Arankalle, 2010, Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients, PLoS One, 5, e13099, 10.1371/journal.pone.0013099
Lee, 2011, Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults, PLoS One, 6, e26050, 10.1371/journal.pone.0026050
Schulert, 2016, Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza, J Infect Dis, 213, 1180, 10.1093/infdis/jiv550
Baseler, 2016, An acute immune response to Middle East respiratory syndrome coronavirus replication contributes to viral pathogenicity, Am J Pathol, 186, 630, 10.1016/j.ajpath.2015.10.025
Arabi, 2014, Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection, Ann Intern Med, 160, 389, 10.7326/M13-2486
Ng, 2016, Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014, Am J Pathol, 186, 652, 10.1016/j.ajpath.2015.10.024
Grom, 2016, Macrophage activation syndrome in the era of biologic therapy, Nat Rev Rheumatol, 12, 259, 10.1038/nrrheum.2015.179
Carlisle, 2019, A banner year for immunotherapy and targeted therapy, Nat Rev Clin Oncol, 16, 79, 10.1038/s41571-018-0138-4
Kumar, 2017, Future prospects of biologic therapies for immunologic diseases, Immunol Allergy Clin North Am, 37, 431, 10.1016/j.iac.2017.01.013
Frey, 2019, Cytokine release syndrome with chimeric antigen receptor T cell therapy, Biol Blood Marrow Transplant, 25, e123, 10.1016/j.bbmt.2018.12.756
Verdoni, 2020, An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study, Lancet, 395, 1771, 10.1016/S0140-6736(20)31103-X
Jones, 2020, COVID-19 and Kawasaki disease: novel virus and novel case, Hosp Pediatr, 10, 537, 10.1542/hpeds.2020-0123
Riphagen, 2020, Hyperinflammatory shock in children during COVID-19 pandemic, Lancet, 395, 1607, 10.1016/S0140-6736(20)31094-1
European Centre for Disease Prevention and Control
Deza Leon, 2020, COVID-19-associated pediatric multisystem inflammatory syndrome, J Pediatric Infect Dis Soc, 9, 407, 10.1093/jpids/piaa061
Centers for Disease Control and Prevention
Zhang, 2020, First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab, Blood Adv, 4, 1307, 10.1182/bloodadvances.2020001907
Michot, 2020, Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report, Ann Oncol, 31, 961, 10.1016/j.annonc.2020.03.300
Luo, 2020, Tocilizumab treatment in COVID-19: a single center experience, J Med Virol, 92, 814, 10.1002/jmv.25801
De Luna, 2020, Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab, Am J Hematol, 95, 876, 10.1002/ajh.25833
Di Giambenedetto, 2020, Off-label use of tocilizumab in patients with SARS-CoV-2 infection [manuscript published online ahead of print April 16, 2020], J Med Virol, 10.1002/jmv.25897
Chiotos, 2020, Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series, J Pediatric Infect Dis Soc, 9, 393, 10.1093/jpids/piaa069
Gotzinger, 2020, COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study [manuscript published online ahead of print June 25, 2020], Lancet Child Adolesc Health, 10.1016/S2352-4642(20)30177-2
Derespina, 2020, Clinical manifestations and outcomes of critically ill children and adolescents with COVID-19 in New York City [manuscript published online ahead of print July 15, 2020], J Pediatr, 10.1016/j.jpeds.2020.07.039
Menter, 2020, Post-mortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction [manuscript published online ahead of print May 4, 2020], Histopathology, 10.1111/his.14134
Wichmann, 2020, Autopsy findings and venous thromboembolism in patients with COVID-19 [manuscript published online ahead of print May 6, 2020], Ann Intern Med
Henry, 2020, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis, Clin Chem Lab Med, 58, 1021, 10.1515/cclm-2020-0369
Connors, 2020, COVID-19 and its implications for thrombosis and anticoagulation, Blood, 135, 2033, 10.1182/blood.2020006000
Yang, 2020, Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19, J Allergy Clin Immunol, 146, 119, 10.1016/j.jaci.2020.04.027
Wen, 2020, Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing, Cell Discov, 6, 31, 10.1038/s41421-020-0168-9
Hadjadj, 2020, Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients, Science, 369, 718, 10.1126/science.abc6027
Trouillet-Assant, 2020, Type I IFN immunoprofiling in COVID-19 patients, J Allergy Clin Immunol, 146, 206, 10.1016/j.jaci.2020.04.029
Blanco-Melo, 2020, Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell, 181, 1036, 10.1016/j.cell.2020.04.026
Channappanavar, 2016, Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice, Cell Host Microbe, 19, 181, 10.1016/j.chom.2016.01.007
Aouba, 2020, Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series [manuscript published online ahead of print May 6, 2020], Ann Rheum Dis, 10.1136/annrheumdis-2020-217706
Cavalli, 2020, Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study, Lancet Rheumatol, 2, e325, 10.1016/S2665-9913(20)30127-2
Dimopoulos, 2020, Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis, Cell Host Microbe, 28, 117, 10.1016/j.chom.2020.05.007
Alattar, 2020, Tocilizumab for the treatment of severe coronavirus disease 2019 [manuscript published online ahead of print May 5, 2020], J Med Virol, 10.1002/jmv.25964
Uciechowski, 2020, Interleukin-6: a masterplayer in the cytokine network, Oncology, 98, 131, 10.1159/000505099
Kopf, 1994, Impaired immune and acute-phase responses in interleukin-6-deficient mice, Nature, 368, 339, 10.1038/368339a0
Harker, 2011, Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection, Science, 334, 825, 10.1126/science.1208421
Kuo, 2009, HBV replication is significantly reduced by IL-6, J Biomed Sci, 16, 41, 10.1186/1423-0127-16-41
Lauder, 2013, Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology, Eur J Immunol, 43, 2613, 10.1002/eji.201243018
US Food and Drug Administration
Lau, 2013, Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment, J Gen Virol, 94, 2679, 10.1099/vir.0.055533-0
Zhou, 2014, Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis, J Infect Dis, 209, 1331, 10.1093/infdis/jit504
Wang, 2007, Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway, Virus Res, 128, 1, 10.1016/j.virusres.2007.02.007
Zhang, 2007, Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB, Virology, 365, 324, 10.1016/j.virol.2007.04.009
Cameron, 2012, Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model, PLoS One, 7, e45842, 10.1371/journal.pone.0045842
Chen, 2020, Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients [manuscript published online ahead of print April 17, 2020], Clin Infect Dis, 10.1093/cid/ciaa449
Ruan, 2020, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med, 46, 846, 10.1007/s00134-020-05991-x
Xu, 2020, Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding, Nat Med, 26, 502, 10.1038/s41591-020-0817-4
Somers, 2020, Tocilizumab for treatment of mechanically ventilated patients with COVID-19 [manuscript published online ahead of print July 11, 2020], Clin Infect Dis, 10.1093/cid/ciaa954
Guaraldi, 2020, Tocilizumab in patients with severe COVID-19: a retrospective cohort study, Lancet Rheumatol, 10.1016/S2665-9913(20)30173-9
Price, 2020, Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes [manuscript published online ahead of print June 15, 2020], Chest
Sciascia, 2020, Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19, Clin Exp Rheumatol, 38, 529
Campochiaro, 2020, Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study, Eur J Intern Med, 76, 43, 10.1016/j.ejim.2020.05.021
Xu, 2020, Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A, 117, 10970, 10.1073/pnas.2005615117
Toniati, 2020, Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy, Autoimmun Rev, 19, 102568, 10.1016/j.autrev.2020.102568
Jacobs, 2018, Pneumatosis intestinalis and intestinal perforation in a patient receiving tocilizumab, Arch Rheumatol, 33, 372, 10.5606/ArchRheumatol.2018.6668
Genovese, 2017, Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis, Arthritis Rheumatol, 69, 1751, 10.1002/art.40176
Morrison, 2020, Letter to the Editor: acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab [manuscript published online ahead of print April 21, 2020], J Med Virol, 10.1002/jmv.25907
Huet, 2020, Anakinra for severe forms of COVID-19: a cohort study, Lancet Rheumatol, 2, e393, 10.1016/S2665-9913(20)30164-8
Ucciferri, 2020, Canakinumab in a subgroup of patients with COVID-19, Lancet Rheumatol, 10.1016/S2665-9913(20)30167-3
Chung, 2009, Critical regulation of early Th17 cell differentiation by interleukin-1 signaling, Immunity, 30, 576, 10.1016/j.immuni.2009.02.007
Cahill, 2008, Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1, J Biol Chem, 283, 25900, 10.1074/jbc.M707692200
Cavalli, 2018, Anakinra therapy for non-cancer inflammatory diseases, Front Pharmacol, 9, 1157, 10.3389/fphar.2018.01157
Dubois, 2011, Rilonacept and canakinumab, Br J Clin Pharmacol, 71, 639, 10.1111/j.1365-2125.2011.03958.x
Nuki, 2002, Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, 2838, 10.1002/art.10578
Cohen, 2004, A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate, Ann Rheum Dis, 63, 1062, 10.1136/ard.2003.016014
Ilowite, 2014, Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis, Arthritis Rheumatol, 66, 2570, 10.1002/art.38699
Hoffman, 2008, Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies, Arthritis Rheum, 58, 2443, 10.1002/art.23687
Koné-Paut, 2011, Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study, Arthritis Res Ther, 13, R202, 10.1186/ar3535
De Benedetti, 2018, Canakinumab for the treatment of autoinflammatory recurrent fever syndromes, N Engl J Med, 378, 1908, 10.1056/NEJMoa1706314
Ruperto, 2012, Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis, N Engl J Med, 367, 2396, 10.1056/NEJMoa1205099
Shakoory, 2016, Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial, Crit Care Med, 44, 275, 10.1097/CCM.0000000000001402
Miettunen, 2011, Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients, Rheumatology (Oxford), 50, 417, 10.1093/rheumatology/keq218
Eloseily, 2020, Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis, Arthritis Rheumatol, 72, 326, 10.1002/art.41103
Rajasekaran, 2014, Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children, Pediatr Crit Care Med, 15, 401, 10.1097/PCC.0000000000000078
Heney, 1995, Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement, Ann Clin Biochem, 32(Pt 4), 358, 10.1177/000456329503200402
Chen, 2019, Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome, Front Microbiol, 10, 50, 10.3389/fmicb.2019.00050
Nieto-Torres, 2015, Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome, Virology, 485, 330, 10.1016/j.virol.2015.08.010
Siu, 2019, Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC, FASEB J, 33, 8865, 10.1096/fj.201802418R
Shi, 2019, SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes, Cell Death Discov, 5, 101, 10.1038/s41420-019-0181-7
Duan, 2003, Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome [in Chinese], Zhonghua Gan Zang Bing Za Zhi, 11, 493
Wong, 2004, Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome, Clin Exp Immunol, 136, 95, 10.1111/j.1365-2249.2004.02415.x
Ng, 2004, Inflammatory cytokine profile in children with severe acute respiratory syndrome, Pediatrics, 113, e7, 10.1542/peds.113.1.e7
He, 2006, Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS, J Pathol, 210, 288, 10.1002/path.2067
Saccomanno, 2019, Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis, J Rheumatol, 46, 416, 10.3899/jrheum.180331
Sönmez, 2018, Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature, Clin Rheumatol, 37, 3329, 10.1007/s10067-018-4095-1
Salliot, 2009, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Ann Rheum Dis, 68, 25, 10.1136/ard.2007.083188
Mehta, 2020, Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome, Lancet Rheumatol, 2, e358, 10.1016/S2665-9913(20)30096-5
Monteagudo, 2020, Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome, ACR Open Rheumatol, 2, 276, 10.1002/acr2.11135
Kullenberg, 2016, Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes, Rheumatology (Oxford), 55, 1499, 10.1093/rheumatology/kew208
Klein, 2019, Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry [manuscript published online ahead of print December 17, 2019], Rheumatology (Oxford)
Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0
Shang, 2020, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet, 395, 683, 10.1016/S0140-6736(20)30361-5
Russell, 2020, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet, 395, 473, 10.1016/S0140-6736(20)30317-2
Ratman, 2013, How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering, Mol Cell Endocrinol, 380, 41, 10.1016/j.mce.2012.12.014
Newton, 2017, Glucocorticoid and cytokine crosstalk: feedback, feedforward, and co-regulatory interactions determine repression or resistance, J Biol Chem, 292, 7163, 10.1074/jbc.R117.777318
Rogatsky, 2006, Glucocorticoid modulation of cytokine signaling, Tissue Antigens, 68, 1, 10.1111/j.1399-0039.2006.00599.x
Herold, 2006, Glucocorticoids in T cell apoptosis and function, Cell Mol Life Sci, 63, 60, 10.1007/s00018-005-5390-y
Lee, 2003, A major outbreak of severe acute respiratory syndrome in Hong Kong, N Engl J Med, 348, 1986, 10.1056/NEJMoa030685
Booth, 2003, Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area, JAMA, 289, 2801, 10.1001/jama.289.21.JOC30885
Lew, 2003, Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome, JAMA, 290, 374, 10.1001/jama.290.3.374
Peiris, 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study, Lancet, 361, 1767, 10.1016/S0140-6736(03)13412-5
Lau, 2004, Outcome of coronavirus-associated severe acute respiratory syndrome using a standard treatment protocol, Respirology, 9, 173, 10.1111/j.1440-1843.2004.00588.x
Sung, 2004, Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak, Thorax, 59, 414, 10.1136/thx.2003.014076
Yam, 2007, Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong, J Infect, 54, 28, 10.1016/j.jinf.2006.01.005
Ho, 2003, High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome, Am J Respir Crit Care Med, 168, 1449, 10.1164/rccm.200306-766OC
Chen, 2006, Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience, Chest, 129, 1441, 10.1378/chest.129.6.1441
Lee, 2004, Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients, J Clin Virol, 31, 304, 10.1016/j.jcv.2004.07.006
Stockman, 2006, SARS: systematic review of treatment effects, PLoS Med, 3, e343, 10.1371/journal.pmed.0030343
Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 1, 10.1001/jamacardio.2020.1017
Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, 180, 1, 10.1001/jamainternmed.2020.0994
Fadel, 2020, Early short course corticosteroids in hospitalized patients with COVID-19 [manuscript published online ahead of print May 19, 2020], Clin Infect Dis, 10.1093/cid/ciaa601
Recovery Collaborative Group, 2020, Dexamethasone in hospitalized patients with Covid-19—preliminary report [manuscript published online ahead of print July 17, 2020], N Engl J Med
Keller, 2020, Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19, J Hosp Med, 10.12788/jhm.3497
Hazbun, 2020, The combination of tocilizumab and methylprednisolone along with initial lung recruitment strategy in coronavirus disease 2019 patients requiring mechanical ventilation: a series of 21 consecutive cases, Crit Care Explor, 2, e0145, 10.1097/CCE.0000000000000145
Callejas Rubio, 2020, Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection, Med Clin (Barc), 155, 159, 10.1016/j.medcli.2020.04.018
Arabi, 2018, Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome, Am J Respir Crit Care Med, 197, 757, 10.1164/rccm.201706-1172OC
Rowe, 2007, Corticosteroids for preventing relapse following acute exacerbations of asthma, Cochrane Database Syst Rev, 3, CD000195
Benchimol, 2008, Traditional corticosteroids for induction of remission in Crohn’s disease, Cochrane Database Syst Rev, 2, CD006792
El-Nawawy, 2017, Evaluation of early corticosteroid therapy in management of pediatric septic shock in pediatric intensive care patients: a randomized clinical study, Pediatr Infect Dis J, 36, 155, 10.1097/INF.0000000000001380
Valoor, 2009, Low-dose hydrocortisone in pediatric septic shock: an exploratory study in a third world setting, Pediatr Crit Care Med, 10, 121, 10.1097/PCC.0b013e3181936ab3
Weiss, 2020, Surviving Sepsis Campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children, Pediatr Crit Care Med, 21, e52, 10.1097/PCC.0000000000002198
Rochwerg, 2018, Corticosteroids in sepsis: an updated systematic review and meta-analysis, Crit Care Med, 46, 1411, 10.1097/CCM.0000000000003262
Annane, 2019, Corticosteroids for treating sepsis in children and adults, Cochrane Database Syst Rev, 12, CD002243
Annane, 2017, Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017, Crit Care Med, 45, 2078, 10.1097/CCM.0000000000002737
Hegenbarth, 2008, Preparing for pediatric emergencies: drugs to consider, Pediatrics, 121, 433, 10.1542/peds.2007-3284
Alhazzani, 2020, Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19), Intensive Care Med, 46, 854, 10.1007/s00134-020-06022-5
World Health Organization
Parikh, 2017, Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome, J Neurol Sci, 380, 11, 10.1016/j.jns.2017.06.044
Hodgins, 2018, Steroid-induced psychosis in the pediatric population: a new case and review of the literature, J Child Adolesc Psychopharmacol, 28, 354, 10.1089/cap.2018.0017
Lee, 2004, Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study, Clin Infect Dis, 39, 1247, 10.1086/424016
Hong, 2004, Avascular necrosis of bone in severe acute respiratory syndrome, Clin Radiol, 59, 602, 10.1016/j.crad.2003.12.008
Lv, 2009, Avascular osteonecrosis after treatment of SARS: a 3-year longitudinal study, Trop Med Int Health, 14(, 79, 10.1111/j.1365-3156.2008.02187.x
Zhao, 2017, Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis, Osteoporos Int, 28, 1027, 10.1007/s00198-016-3824-z
Liu, 2017, A 12-year follow-up study of combined treatment of post-severe acute respiratory syndrome patients with femoral head necrosis, Ther Clin Risk Manag, 13, 1449, 10.2147/TCRM.S140694
Chan, 2004, Osteonecrosis in children with severe acute respiratory syndrome, Pediatr Infect Dis J, 23, 888, 10.1097/01.inf.0000137570.37856.ea
Lansbury, 2020, Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis, Crit Care Med, 48, e98, 10.1097/CCM.0000000000004093
Rutsaert, 2020, COVID-19-associated invasive pulmonary aspergillosis, Ann Intensive Care, 10, 71, 10.1186/s13613-020-00686-4
Thijs, 2019, Adrenal insufficiency, be aware of drug interactions!, Endocrinol Diabetes Metab Case Rep, 2019, 19-0062
Bechman, 2019, A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis, Rheumatology (Oxford), 58, 1755, 10.1093/rheumatology/kez087
Morris, 2018, The molecular details of cytokine signaling via the JAK/STAT pathway, Protein Sci, 27, 1984, 10.1002/pro.3519
O’Shea, 2013, Back to the future: oral targeted therapy for RA and other autoimmune diseases, Nat Rev Rheumatol, 9, 173, 10.1038/nrrheum.2013.7
Huang, 2019, Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis, Pediatrics, 143, e20182845, 10.1542/peds.2018-2845
Kerrigan, 2018, JAK inhibitors in rheumatology: implications for paediatric syndromes?, Curr Rheumatol Rep, 20, 83, 10.1007/s11926-018-0792-7
González Vicent, 2019, Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results, Am J Hematol, 94, 319, 10.1002/ajh.25376
Khandelwal, 2017, Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients, Biol Blood Marrow Transplant, 23, 1122, 10.1016/j.bbmt.2017.03.029
Ahmed, 2019, Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial, Lancet Haematol, 6, e630, 10.1016/S2352-3026(19)30156-5
Sin, 2019, Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report, Hematol Oncol Stem Cell Ther, 12, 166, 10.1016/j.hemonc.2017.07.002
Broglie, 2017, Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis, Blood Adv, 1, 1533, 10.1182/bloodadvances.2017007526
Trantham, 2020, Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: a cautionary tale, J Oncol Pharm Pract, 26, 1005, 10.1177/1078155219878774
Cao, 2020, Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial, J Allergy Clin Immunol, 146, 137, 10.1016/j.jaci.2020.05.019
Titanji, 2020, Use of baricitinib in patients with moderate and severe COVID-19 [published online ahead of print June 29, 2020], Clin Infect Dis
Cantini, 2020, Beneficial impact of baricitinib in COVID-19 moderate pneumonia; multicentre study [published online ahead of print June 24, 2020], J Infect, 10.1016/j.jinf.2020.06.052
Colombel, 2018, Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention, Inflamm Bowel Dis, 24, 2173, 10.1093/ibd/izy150
Richardson, 2020, Baricitinib for COVID-19: a suitable treatment? Authors’ reply [manuscript published online ahead of print April 2, 2020], Lancet Infect Dis, 10.1016/S1473-3099(20)30270-X
He, 2013, Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis, BMC Musculoskelet Disord, 14, 298, 10.1186/1471-2474-14-298
Gaspari, 2020, Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports, Int J Antimicrob Agents, 56, 106023, 10.1016/j.ijantimicag.2020.106023
Middeldorp, 2020, Incidence of venous thromboembolism in hospitalized patients with COVID-19, J Thromb Haemost, 18, 1995, 10.1111/jth.14888
US Food and Drug Administration
Veeravalli, 2020, Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved Janus kinase inhibitors for rheumatoid arthritis treatment, Drug Saf, 43, 711, 10.1007/s40264-020-00938-z
Casadevall, 2020, The convalescent sera option for containing COVID-19, J Clin Invest, 130, 1545, 10.1172/JCI138003
Cheng, 2005, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis, 24, 44, 10.1007/s10096-004-1271-9
Soo, 2004, Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients, Clin Microbiol Infect, 10, 676, 10.1111/j.1469-0691.2004.00956.x
Ko, 2018, Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience, Antivir Ther, 23, 617, 10.3851/IMP3243
Mair-Jenkins, 2015, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J Infect Dis, 211, 80, 10.1093/infdis/jiu396
Shen, 2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA, 323, 1582, 10.1001/jama.2020.4783
Zhang, 2020, Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection, Chest, 158, e9, 10.1016/j.chest.2020.03.039
Duan, 2020, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A, 117, 9490, 10.1073/pnas.2004168117
Ahn, 2020, Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea, J Korean Med Sci, 35, e149, 10.3346/jkms.2020.35.e149
Ye, 2020, Treatment with convalescent plasma for COVID-19 patients in Wuhan, China [manuscript published online ahead of print April 15, 2020], J Med Virol, 10.1002/jmv.25882
Li, 2020, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, 324, 1, 10.1001/jama.2020.10044
Qu, 2020, Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [manuscript published online ahead of print April 27, 2020], Clin Infect Dis, 10.1093/cid/ciaa489
Long, 2020, Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, Nat Med, 26, 1200, 10.1038/s41591-020-0965-6
Zhang, 2020, Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19, Aging (Albany NY), 12, 6536, 10.18632/aging.103102
Zeng, 2020, Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients, J Infect Dis, 222, 38, 10.1093/infdis/jiaa228
Figlerowicz, 2020, First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia [manuscript published online ahead of print July 1, 2020], Transfus Apher Sci, 10.1016/j.transci.2020.102866
Wan, 2020, Molecular mechanism for antibody-dependent enhancement of coronavirus entry, J Virol, 94:e02015-19
Food and Drug Administration
Liu, 2019, Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection, JCI Insight, 4, e123158, 10.1172/jci.insight.123158
Crowe, 2001, Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines, J Immunol, 167, 3910, 10.4049/jimmunol.167.7.3910
Murphy, 1986, Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection, J Clin Microbiol, 23, 1009, 10.1128/JCM.23.6.1009-1014.1986
Bloch, 2020, Deployment of convalescent plasma for the prevention and treatment of COVID-19, J Clin Invest, 130, 2757, 10.1172/JCI138745
Díez, 2020, Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens, Immunotherapy, 12, 571, 10.2217/imt-2020-0095
Samuelsson, 2001, Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor, Science, 291, 484, 10.1126/science.291.5503.484
Siedlar, 2011, Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients, Clin Immunol, 139, 122, 10.1016/j.clim.2011.01.002
Othy, 2013, Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis, J Immunol, 190, 4535, 10.4049/jimmunol.1201965
Perez, 2017, Update on the use of immunoglobulin in human disease: a review of evidence, J Allergy Clin Immunol, 139, S1, 10.1016/j.jaci.2016.09.023
Wohlfarth, 2019, Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis, J Intensive Care Med, 34, 723, 10.1177/0885066617711386
Yang, 2005, Thrombocytopenia in patients with severe acute respiratory syndrome (review), Hematology, 10, 101, 10.1080/10245330400026170
Van Dyne, 2019, Incidence and outcome of severe and nonsevere thrombocytopenia associated with Zika virus infection—Puerto Rico, 2016, Open Forum Infect Dis, 6, ofy325, 10.1093/ofid/ofy325
Lippi, 2020, Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis, Clin Chim Acta, 506, 145, 10.1016/j.cca.2020.03.022
Cao, 2020, High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019, Open Forum Infect Dis, 7, ofaa102, 10.1093/ofid/ofaa102
Ye, 2019, Interferon-λ orchestrates innate and adaptive mucosal immune responses, Nat Rev Immunol, 19, 614, 10.1038/s41577-019-0182-z
Prokunina-Olsson, 2020, COVID-19 and emerging viral infections: the case for interferon lambda, J Exp Med, 217, e20200653, 10.1084/jem.20200653
Muir, 2014, A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection, J Hepatol, 61, 1238, 10.1016/j.jhep.2014.07.022
Agarwal, 2018, 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection, J Hepatol, 68, 672, 10.1016/j.jhep.2017.11.039
Korean Association for the Study of the Liver., 2019, KASL clinical practice guidelines for management of chronic hepatitis B, Clin Mol Hepatol, 25, 93, 10.3350/cmh.2019.1002
Chu, 2020, Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 [manuscript published online ahead of print April 9, 2020], Clin Infect Dis, 10.1093/cid/ciaa410
O’Brien, 2020, Weak induction of interferon expression by SARS-CoV-2 supports clinical trials of interferon lambda to treat early COVID-19 [manuscript published online ahead of print April 17, 2020], Clin Infect Dis, 10.1093/cid/ciaa453
Hung, 2020, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet, 395, 1695, 10.1016/S0140-6736(20)31042-4
Gaeta, 2002, Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C, Aliment Pharmacol Ther, 16, 1633, 10.1046/j.1365-2036.2002.01331.x
Raison, 2005, Neuropsychiatric adverse effects of interferon-alpha: recognition and management, CNS Drugs, 19, 105, 10.2165/00023210-200519020-00002
Planet, 2016, Lambda interferon restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection, mBio, 7, e01939, 10.1128/mBio.01939-15
Davidson, 2015, Disease-promoting effects of type I interferons in viral, bacterial, and coinfections, J Interferon Cytokine Res, 35, 252, 10.1089/jir.2014.0227